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Abstract 
Purpose: Recently, the US FDA has approved “vagal blocking therapy or vBLoc® therapy” 
as a new treatment for obesity. The aim of the present study was to study the mechanism-of-
action of “VBLOC” in rat models.  
Materials and Methods: Rats were implanted with VBLOC, an intra-abdominal electrical 
device with leads placed around gastric vagal trunks through an abdominal incision and 
controlled by wireless device. Body weight, food intake, hunger/satiety, and metabolic 
parameters were monitored by a comprehensive laboratory animal monitoring system. Brain-
gut responses were analyzed physiologically.   
Results: VBLOC reduced body weight and food intake, which was associated with increased 
satiety but not with decreased hunger. Brain activities in response to VBLOC included 
increased gene expression of leptin- and CCKb-receptors, interleukin-1β, tumor necrosis 
factor and transforming growth factor β1 in the brainstem, increased CCK, somatostatin and 
tyrosine hydroxylase in the hippocampus, increased NPY, AgRP and Foxa2 in the 
hypothalamus, and reduced CCKb receptor, melanocortin 4 receptor and insulin receptor in 
the hypothalamus. Plasma concentrations of CCK, gastrin, glucagon, GLP-1 and PYY and 
gastric acid secretion were unchanged in response to VBLOC.   
Conclusion: Based on the present study, we suggest that VBLOC induces satiety through 
vagal signaling, leading to reduced food intake and loss of body weight. 
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Introduction 
 The number of obese individuals is increasing rapidly, leading to a global obesity 
epidemic. So far, only bariatric surgery has demonstrated long-term therapeutic effects, and 
therefore the use of surgery to treat obesity is increasing (1, 2). Considering the large number 
of obese patients, the risk of surgical complications and high surgery-related cost, the 
development of minimal invasive procedures to treat obesity is urgently needed (3).  
The gut-brain axis is known to play an important role in the pathogenesis of obesity. 
Nutritional and metabolically relevant information is conveyed to the brain by gut-produced 
hormones and the vagus nerve (4). The vagus nerve responds to mechanical and chemical 
stimuli from the gastrointestinal tract and transmits satiety signals to sites in the central 
nervous system that regulate eating behavior (5-7). Through the nucleus of the tractus 
solitarius (NTS) in the brainstem, afferent vagal signals may be relayed to reach several parts 
of the brain including the parabrachial nucleus, reticular formation, hippocampus, amygdala 
and hypothalamus (8). The hypothalamus is regarded as a key regulatory component of a 
central network for food intake where orexigenic neuropeptide Y (NPY) and agouti-related 
peptide (AgRP) neurons and anorexigenic pro-opiomelanocortin (POMC) and cocaine- and 
amphetamine-regulated transcript (CART) neurons are thought to play a central role (5). 
However, the brainstem also contributes in food intake and body weight regulation (9). In 
addition to the regulation of food intake, the vagus nerve also regulates gastric acid 
production and pancreatic secretion (10, 11). The central role of the vagus in the regulation of 
food intake and energy expenditure makes it an ideal target for new less or non-invasive 
procedures to treat obesity. 
Recently, the US FDA has approved “vagal blocking therapy or vBLoc® therapy” by 
which an intra-abdominal electrical device with leads is placed laparoscopically around the 
vagus nerve as a new treatment for obesity (12, 13). The term VBLOC has been often used in 
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clinical trials, patent applications and the US FDA approval documents. VBLOC was initially 
believed to be of “vagotomy effect” but in fact this is unlikely as pointed out by the FDA 
approval letter, i.e. “the specific mechanisms for weight loss due to the use of the device are 
unknown”. Hence, the aim of this study was to study the mechanism-of-action (MOA). To 
this end, we utilized animal models to examine how VBLOC impacted upon body weight, 
food intake, hunger/satiety, eating behavior, metabolic parameters, gut hormone 
concentrations, gastric acid secretion and the expression profile of candidate energy balance-
regulating genes in the hypothalamus, brainstem and hippocampus.  
 
Materials and methods 
Animals  
Rats (adult, male, Sprague-Dawley) were purchased from Taconic (Ejby, Denmark) 
and Janvier Labs (France). Rats (adult, female, Long Evan) were obtained at NTNU, 
Trondheim, Norway. They had free access to tap water and standard rat pellet food (RM1 
811004, Scanbur BK AS, Sweden). Three to four animals were housed together in 
individually ventilated cages on wood chip bedding with a 12-hour light/dark cycle, room 
temperature of 22ºC and 40-60% relative humidity. The standard housing conditions were 
specific pathogen free and in agreement with FELASA (Federation of European Laboratory 
Animal Science Association) recommendations. All animals were euthanized between 0800-
1000 A.M. Thus, the plasma concentrations of gut hormones measured at sacrifice could be 
considered as post prandial levels. Animal experiments were performed according to the 
guidelines for the design and statistical analysis of experiments using laboratory animals after 
being approved by the Norwegian National Animal Research Authority (Forsøksdyrutvalget, 
FDU). All applicable institutional and national guidelines for the care and use of animals were 
followed. 
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In all studies regarding eating behaviour the animals were acclimatized to the 
Comprehensive Laboratory Animal Monitoring System (CLAMS; Columbus Instruments 
International, Columbus, OH USA) for 24h before data collection. At data collection the 
animals were kept in CLAMS for 48h, and data from the last 24h were used for analysis. 
Before CLAMS the rats were habituated to their normal food as powder for three days, as the 
food in CLAMS is in powder form. Body weight development was followed throughout the 
study period (three times per week).  
 
Experimental design 
Pilot experiment 
The paradigm of VBLOC between 0.5mA – 2.0 mA with 30 Hz, 500 µs, 30 s ON and 5 min 
OFF was chosen according to the safety, tolerance and possible efficacy assessments in 
response to the long-term VBLOC. 
 
Short-term VBLOC 
In the first experiment, rats (Sprague-Dawley) received VBLOC (2 mA, 30 Hz, 500 
µs, 30 s ON and 5 min OFF) while they were subjected to in vivo electrophysiological 
recording in the hippocampus. In the second experiment, rats (Sprague-Dawley) were 
acclimatized to Bollman cages for 3 hours at 3 separate occasions before and after VBLOC 
and gastric fistula implantation, and then subjected to gastric acid secretion measurement 
(baseline and pentagastrin-stimulation). After gastric acid output measurement, VBLOC was 
turned off. Three days after, rats received VBLOC (2 mA, 30 Hz, 500 µs, 30 s ON and 5 min 
OFF) for 48h while eating behaviour and metabolic parameters were measured in CLAMS 
(14, 15). The animals were randomized into VBLOC and control groups (6 rats per group). 
The control group received the same implantations without any stimulation. Immediately after 
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48h of VBLOC, the rats were euthanized and brain samples were collected for in situ 
hybridization, and plasma was collected for radioimmunoassay.  
 
Long-term VBLOC 
In the first experiment (Sprague-Dawley rats), VBLOC was started 4 weeks after 
implantation of the device which was constantly ON while the current (mA) was gradually 
increased for 6-8 weeks. Each rat was placed in CLAMS at 4 time points for measurements of 
eating behavior and metabolic parameters; 3 weeks after VBLOC implantation (before 
stimulation, baseline), at 0.5 mA stimulation, at 1 mA stimulation and at 2 mA stimulation. 
The settings were 30 Hz, pulse width 500 µs and the ON and OFF time were 30 s and 5 min. 
The VBLOC and control groups consisted of 9 and 4 rats per group, respectively. The control 
group had the same implantation with no stimulation. At euthanization brain samples were 
taken for Taqman array analysis and RNA Sequencing. Plasma was collected for 
radioimmunoassay. In the second experiment (Long Evan rats), smaller VBLOC devices 
(µVBLOC) were developed due to device-size-related irritation. The animals were 
randomized into VBLOC and control groups (4 rats per group). VBLOC was continuously 
ON at 2 mA, 30 Hz, 500 µs, 30 s ON and 5 min OFF for 2 weeks. At euthanization plasma 
was collected for radioimmunoassay. 
 
Statistical Analysis 
The results are expressed as mean ± SEM. Statistical comparisons were performed 
using independent t-test between the surgical groups. ANOVA with Sidak test was performed 
for energy expenditure statistics, while ANOVA with Tukey’s test was performed to 
determine eating behavior and metabolic parameters. A p-value of <0.05 (two-tailed) was 
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considered statistically significant. The data analysis was performed in SPSS version 15.0 and 
20.0. 
 
Supplementary Materials and Methods 
Information regarding animal surgery, determination of eating behavior and metabolic 
parameters, gastric acid output measurement, taqman array, in situ hybridization, RNA 
sequencing, radioimmunoassay, in vivo electrophysiology and statistical analysis are provided 
in the Supplementary Materials and methods.   
 
Results 
In vivo electrophysiology tetrodes recorded VBLOC-induced activity in the brain (Fig. 
1a). In response to the short-term VBLOC (48h at 2 mA current), gene expression of NPY 
and AgRP in the arcuate nucleus (ARC) of the hypothalamus as well as NPY gene expression 
in dorsomedial hypothalamic nucleus (DMH) were up-regulated, but NPY gene expression in 
the brainstem, and plasma concentrations of gut hormones were unchanged (Fig. 1b-e). On 
the other hand, basal and pentagastrin-stimulated gastric acid secretions were unchanged in 
response to the short-term VBLOC (Fig. 1f).  
During the short-term VBLOC (48h at 2 mA current), there were no changes in body 
weight, food intake, eating behavior, and metabolic parameters including energy expenditure 
(Table 1). The animals showed no signs of discomfort stemming from the VBLOC. 
In response to the long-term VBLOC in which the current was gradually increased 
(from 0.5 mA to 2 mA), the body weight and food intake (g) were reduced as the current was 
increased, eventually reaching reductions of 10% (p>0.05) and 30% (p<0.05), respectively 
(Fig. 2a-c). Energy expenditure (kcal/h/body weight) was reduced compared to baseline 
values (Fig. 2d). Satiety ratio particularly during nighttime was increased, but the number of 
8 
 
meals (“hunger index”) was unchanged (Fig. 2e,f). When the current was started at 2 mA, a 
10% body weight reduction was achieved within 1 week (p<0.05) (Fig. 2a). Additional 
parameters of eating behavior and metabolism were unchanged after the long-term VBLOC 
(Table 2).   
Analysis of the hypothalamus showed a significant increase in gene expression of 
NPY and forkhead box protein A2 (Foxa2), a decrease for cholecystokinin b (CCKb) receptor 
and a tendency for decreased expression of the melanocortin 4 receptor (MC4R) and insulin 
receptor (Insr) (Fig. 3a). In the brainstem, the gene expression of leptin- and CCKb -receptors, 
and interleukin-1β (IL1b), tumor necrosis factor (Tnf) and transforming growth factor β1 
(Tgfb1) was increased (Fig. 3b). In the hippocampus, VBLOC increased expression of CCK, 
somatostatin and tyrosine hydroxylase (crucial for the production of dopamine) (Fig. 3c,d). 
The plasma concentrations of CCK, gastrin, glucagon, glucagon-like peptide-1 (GLP-1) and 
peptide YY (PYY) were unchanged (Fig. 3e,f).  
 
Discussion  
The brain-gut axis functions in both afferent and efferent directions via the vagus 
nerve. To examine the effects of VBLOC on either efferent or afferent or both directions, the 
gut responses (gastric acid secretion and gut hormones) and the brain responses (electrical 
activity and gene expression) were analyzed. VBLOC was originally derived from vagus 
nerve stimulation. In the neuromodulation spectrum, it has been postulated that low frequency 
electrical impulses increases the neurophysiologic activity, resulting in neurostimulation. The 
converse occurs with higher frequency electrical impulses, resulting in neuroblocking. In the 
present study the two electrodes of VBLOC were wrapped around both the anterior and 
posterior nerve branches together with extra tissue from the esophagus. The cathode was 
placed on the proximal part and anode on the distal part (Fig. 4a). During VBLOC the cathode 
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induced depolarization, leading to a stimulation of the afferent fibers. The afferent fibers are 
believed to be involved in the sensory feedback on satiety, satiation and energy metabolism. 
As shown in the present study, VBLOC induced satiety signaling in the brainstem and satiety 
ratio (but not hunger) in eating behavior. During VBLOC the distal anode hyperpolarized the 
membrane and imposed an anodic block on the efferent fibers (Fig. 4b). The stimulation of 
vagus nerve is known to induce gastric acid secretion via the efferent fibers on the parietal 
cells and the gastrin-producing G cells in the stomach (16, 17). As shown in the present study, 
VNS did not affect the acid secretion and gut hormones (particularly gastrin, CCK, GLP-1 
and PYY), indicating a functional blockade of vagal efferent fibers, named as VBLOC. The 
long-term application of VBLOC  (6-8 weeks), particularly with the application of the highest 
current for 2 weeks, resulted in reduced food intake and body weight in the rat model. 
Previously, several animal studies reported reduced body weight gain and food intake 
in response to VNS that was applied mostly at the left vagal branch in the neck. However, the 
results reported were of low quality due to large variations, and no SD or SEM values were 
given in the figures (18-23). In the present study, the short-term (48h) VBLOC was unable to 
alter eating behavior. However, the long-term (6-8 weeks) VBLOC, particularly when started 
with a high current (2 weeks), reduced food intake and body weight. This is in line with a 
report that subdiaphragmatic VNS attenuated weight gain in obese minipigs during 14 weeks 
(24). 
It should be noticed that in response to VBLOC, the gene expression, especially 
NPY/AgRP, in the hypothalamus, was unexpectedly changed with a drive for increased food 
intake and a reduction in energy expenditure (5, 25-27). However, the gene expression in the 
brainstem and the hippocampus was changed, which was compatible with an anorexigenic 
drive in response to VBLOC, being consistent with the weight loss. The brainstem is the first 
target for vagal afferent fibers in the central nervous system. VBLOC-induced afferent signals 
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can be sent from the brainstem to the hippocampus, which has also been observed  in previous 
studies (28). In fact, the hippocampus is not only involved in memory, but also has a role in 
incentive motivation (e.g. for food), in the processing of hormonal signals (CCK, ghrelin, and 
motilin), and in the regulation of food intake (29-33).  
Gut hormones are thought to be central in appetite regulation in the gut-brain axis, and 
satiety hormones such as CCK, glucagon, GLP-1, and PYY are known to reduce food intake 
(4). However, these gut hormones were unaltered after both short and long-term VBLOC. 
Thus, we speculate that there are the two pathways, i.e. gut hormone – hypothalamus and 
vagus nerve – brainstem, within the gut-brain axis, and that these are independent each other. 
Ghrelin levels were not included due to a technical problem. However, it is unlikely that 
ghrelin plays a role in VBLOC-induced weight loss, because  the hunger index was not 
changed  during both daytime and nighttime.  
Taken together, we suggest that the VBLOC, by activating the vagal signaling to the 
brainstem and hippocampus and blocking the vagal signaling to the gut, leads to increased 
satiety, reduced food intake and eventually the loss of body weight. It is our hope that this 
study will serve as the basis for many more experimental studies to better understand the 
mechanism-of-action of VBLOC therapy in the future.  
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Figure Legends 
Fig. 1: The effects of short-term VBLOC. A. In vivo electrophysiological recordings of 
stimulation-induced activity in the brain. The graph depicts the average waveform of 
measured activity, the insert show the raw data from which the average waveform was 
constructed. B. Effects of short-term VBLOC (48h) on mRNA expression of NPY, AgRP and 
POMC in the arcuate nucleus (ARC) and dorsomedial hypothalamic nucleus (DMH). 
*:p<0.05 between sham-VBLOC (white) and VBLOC (black). C. Effect of short-term 
VBLOC (48h) on NPY expression in the brainstem. Note: no significant difference between 
sham-VBLOC (white) and VBLOC (black). D&E. Effects of short-term VBLOC (48h) on 
plasma concentrations of gut hormones. Note: no significant difference between sham-
VBLOC (white) and VBLOC (black). F. Effects of VBLOC on baseline and pentagastrin 
(PG)-stimulated gastric acid secretion. Note: no significant difference between any VBLOC 
currents with or without PG injection.   
Fig. 2: The effects of long-term VBLOC on body weight, eating behavior and metabolic 
parameters. A. Effects of different currents of VBLOC on body weight. Note: when current 
was started at 2 mA a weight reduction was accomplished instantly (p<0.05) (white). B. 
Effects of long-term VBLOC on food intake (g/24h). *:p<0.05 between sham-VBLOC 
(white) and VBLOC (black). C. Effects of long-term VBLOC on food intake (g/100g body 
weight). *:p<0.05 between values before VBLOC and at 2 mA. Note: white columns 
represent sham-VBLOC, black columns represent VBLOC. D. Effect of long-term VBLOC 
on energy expenditure (kcal/h/body weight). **:p<0.01 between values before VBLOC and at 
2 mA (ANCOVA with Sidak test). Note: white columns represent sham-VBLOC, black 
columns represent VBLOC. E. Effects of long-term VBLOC on satiety ratio (min/g) during 
nighttime. Note: *p<0.05 (one-tailed) between sham-VBLOC (white) and VBLOC (black) at 
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2 mA. F. Effects of long-term VBLOC on number of meals (24h). Note: no significant 
difference between sham-VBLOC (white) and VBLOC (black).  
Fig. 3: The effects of long-term VBLOC (2 mA) on brain gene expression and gut 
hormones. A. Effects of long-term VBLOC (2 mA) on hypothalamic mRNA expression of 
neuropeptide Y (NPY), forkhead box protein A2 (Foxa2), CCKb receptor, melanocortin 4 
receptor (Mc4r) and insulin receptor (Insr). *:p<0.05 between sham-VBLOC (white) and 
VBLOC (black). Note: p=0.067 on Insr and p=0.086 on Mc4r (two-tailed). B. Effects of long-
term VBLOC (2 mA) on mRNA expression of leptin receptor (Lepr) and CCKB/2 receptor 
(Cckbr), interleukin-1β (IL1b), tumor necrosis factor (Tnf) and transforming growth factor β1 
(Tgfb1) in the brainstem. *:p<0.05 between sham-VBLOC (white) and VBLOC (black). 
C&D. Effects of long-term VBLOC (2 mA) on mRNA expression of CCK, somatostatin and 
tyrosine hydroxylase in hippocampus. *, **, ***:p<0.05, 0.01, 0.001 between sham-VBLOC 
(white) and VBLOC (black). E&F. Effects of long-term VBLOC (2 mA) on plasma 
concentrations of gut hormones. Note: no significant difference between sham-VBLOC 
(white) and VBLOC (black).  
Fig. 4: Overview of VBLOC device position and function. A. Photograph showing the 
position of the implanted VBLOC electrodes around the gastric vagus nerve in a rat. B. 
Drawing illustrating how the cathode induces depolarization and stimulation of the afferent 
fibers, while the anode hyperpolarizes the membrane and imposes an anodic block on the 
efferent fibers. 
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Table 1: Responses of body weight, food intake, eating behavior and metabolic parameters to 
short-term VBLOC at 2 mA.  
  Parameters 
Sham-VBLOC 
(n=6) 
VBLOC 2 mA  
short-term (n=6) p-value 
 Body weight 401.87±10.05 371.88±10.63 0.068 
24 hours 
Food intake (g) 25.58±1.69 25.48±1.51 0.966 
Food intake (g/100g body weight) 6.6±0.44 6.99±0.37 0.517 
Calories intake (kcal) 65.37±4.35 65.47±3.89 0.966 
Calories intake (kcal/100g body weight) 16.95±1.14 17.95±0.96 0.517 
Number of meals 25.5±6.43 24±8.25 0.889 
Meal size (g/meal) 1.24±0.19 1.47±0.27 0.490 
Meal size (kcal/meal) 3.18±0.5 3.79±0.69 0.490 
Satiety ratio (min/g) 51.37±3.91 50.66±3.58 0.895 
Rate of eating (g/min) 0.29±0.03 0.25±0.02 0.286 
Energy expenditure (kcal/h) 2.24±0.04 2.03±0.09 0.072 
Energy expenditure (kcal/h/100g body weight) 0.58±0.01 0.56±0.02 0.357 
Energy expenditure (kcal/h/cm2 body surface) 0.005±0 0.005±0 0.187 
RER 1.13±0.01 1.1±0.03 0.260 
Daytime 
Food intake (g) 9.41±0.92 9.91±0.99 0.715 
Food intake (g/100g body weight) 2.43±0.24 2.72±0.26 0.429 
Calories intake (kcal) 24.17±2.37 25.48±2.54 0.715 
Calories intake (kcal/100g body weight) 6.23±0.62 6.99±0.67 0.429 
Number of meals 10.33±3.03 11±5.05 0.912 
Meal size (g/meal) 1.2±0.21 1.55±0.38 0.432 
Meal size (kcal/meal) 3.09±0.54 3.99±0.96 0.432 
Satiety ratio (min/g) 68.12±7.09 63.27±6.7 0.629 
Rate of eating (g/min) 0.3±0.02 0.28±0.02 0.506 
Energy expenditure (kcal/h) 1.92±0.07 2.09±0.04 0.074 
Energy expenditure (kcal/h/100g body weight) 0.54±0.01 0.53±0.01 0.490 
Energy expenditure (kcal/h/cm2 body surface) 0.004±0 0.004±0 0.201 
RER 1.11±0.02 1.08±0.02 0.305 
Nighttime 
Food intake (g) 16.17±1.02 15.56±1.67 0.763 
Food intake (g/100g body weight) 4.17±0.27 4.27±0.45 0.857 
Calories intake (kcal) 41.56±2.63 39.99±4.3 0.763 
Calories intake (kcal/100g body weight) 10.72±0.69 10.96±1.14 0.857 
Number of meals 15.17±3.49 13±3.32 0.662 
Meal size (g/meal) 1.27±0.19 1.49±0.27 0.522 
Meal size (kcal/meal) 3.28±0.48 3.84±0.7 0.522 
Satiety ratio (min/g) 38.46±2.81 40.66±4.83 0.701 
Rate of eating (g/min) 0.28±0.03 0.23±0.03 0.217 
Energy expenditure (kcal/h) 2.38±0.05 2.13±0.12 0.093 
Energy expenditure (kcal/h/100g body weight) 0.61±0.01 0.58±0.03 0.316 
Energy expenditure (kcal/h/cm2 body surface) 0.005±0 0.005±0 0.192 
RER 1.15±0.02 1.11±0.03 0.257 
Data are expressed as means ± SEM. No significant difference between sham-VBLOC and VBLOC (two-tailed). 
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Table 2: Responses of food intake, eating behavior and metabolic parameters to long-term 
VBLOC at 2 mA. 
  Parameters 
Sham-VBLOC 
(n=4) 
VBLOC 2 mA  
long-term (n=9) p-value 
24 hours 
Food intake (g) 23.03±1.1 15.22±2.74 0.024*  
Food intake (g/100g body weight) 5.44±0.65 3.93±0.65 0.192 
Calories intake (kcal) 59.17±2.83 39.13±7.04 0.024*  
Calories intake (kcal/100g body weight) 13.99±1.66 10.11±1.68 0.192 
Number of meals 17.5±2.6 21.11±9.14 0.803 
Meal size (g/meal) 1.38±0.15 1.51±0.43 0.782 
Meal size (kcal/meal) 3.54±0.38 3.87±1.12 0.782 
Satiety ratio (min/g) 56.6±2.7 164.02±61.51 0.119 
Rate of eating (g/min) 0.36±0.04 0.28±0.04 0.229 
Energy expenditure (kcal/h) 2.26±0.08 1.92±0.12 0.095 
Energy expenditure (kcal/h/100g body weight) 0.53±0.06 0.49±0.02 0.417 
Energy expenditure (kcal/h/cm2 body surface) 0.005±0 0.004±0 0.218 
RER 1.18±0.01 1.08±0.03 0.063 
Daytime 
Food intake (g) 5.94±1.7 5.15±1.04 0.692 
Food intake (g/100g body weight) 1.5±0.55 1.38±0.29 0.836 
Calories intake (kcal) 15.26±4.38 13.25±2.68 0.692 
Calories intake (kcal/100g body weight) 3.85±1.4 3.55±0.74 0.836 
Number of meals 5.75±1.18 7.56±3.89 0.770 
Meal size (g/meal) 0.99±0.17 1.43±0.43 0.369 
Meal size (kcal/meal) 2.54±0.44 3.67±1.11 0.369 
Satiety ratio (min/g) 129.53±35.36 4180.21±3966.1 0.520 
Rate of eating (g/min) 0.35±0.05 0.28±0.05 0.447 
Energy expenditure (kcal/h) 2.1±0.1 1.83±0.09 0.103 
Energy expenditure (kcal/h/100g body weight) 0.5±0.06 0.47±0.02 0.532 
Energy expenditure (kcal/h/cm2 body surface) 0.004±0 0.004±0 0.285 
RER 1.15±0.03 1.06±0.03 0.080 
Nighttime 
Food intake (g) 17.09±2.02 10.07±2.02 0.061 
Food intake (g/100g body weight) 3.94±0.35 2.55±0.46 0.087 
Calories intake (kcal) 43.91±5.2 25.88±5.19 0.061 
Calories intake (kcal/100g body weight) 10.14±0.9 6.56±1.18 0.087 
Number of meals 11.75±3.3 13.56±5.41 0.837 
Meal size (g/meal) 1.64±0.23 1.66±0.52 0.983 
Meal size (kcal/meal) 4.22±0.59 4.26±1.34 0.983 
Satiety ratio (min/g) 36.85±3.52 103.58±32.29 0.073 
Rate of eating (g/min) 0.37±0.04 0.27±0.04 0.137 
Energy expenditure (kcal/h) 2.41±0.07 2.02±0.14 0.098 
Energy expenditure (kcal/h/100g body weight) 0.57±0.06 0.52±0.03 0.346 
Energy expenditure (kcal/h/cm2 body surface) 0.005±0 0.004±0 0.190 
RER 1.21±0.01 1.11±0.03 0.015* 
Data are expressed as means ± SEM. *:p<0.05 between sham-VBLOC and VBLOC (two-tailed). 
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Animal surgery 
All surgeries were performed under general anesthesia with isofluran (4% for 
induction, 2% for maintenance). Atropin was given at a dose of 0.04 mg/kg subcutaneously 
20 min before anesthesia. Buprenorphine was injected subcutaneously (0.05 mg/kg) 
immediately after surgery in all animals, and one day postoperatively when needed. 
Physiological saline (0.9% NaCl) was given subcutaneously at 10 mL after surgeries to keep 
the animals hydrated. 
VBLOC implantation was performed through a midline abdominal incision. The 
subdiaphragmatic truncal vagus nerve was dissected from the esophagus and two electrodes 
(Lead Model 302, Cyberonics, Houston, TX) were wrapped around both the anterior and 
posterior nerve (Fig 4a). The wire from the electrodes was attached to fat tissue around the 
stomach and to the muscular layer using 6-0 and 4-0 absorbable sutures (Vicryl, Ethicon Inc., 
Sommerville, NJ, USA), respectively. On the back of the rat a subcutaneous pocket for the 
stimulator (model 102 Pulse Generator, Cyberonics, Houston, TX) was made and here it was 
connected to the wire. The abdomen was closed in two layers using 4-0 absorbable sutures 
and the back was closed using the same sutures (Ethicon). The control and VBLOC rats 
received the same procedure. Implantation of the µ-VBLOC device followed the same 
procedure. In the gastric acid secretion experiment a gastric fistula was in addition implanted 
in the stomach. Before this procedure the animals were fasted overnight, and after surgery 
they were given water immediately and food the same evening.  
 
Determination of Eating Behavior and Metabolic Parameters 
Rats were placed in the Comprehensive Laboratory Animal Monitoring System 
(CLAMS; Columbus Instruments International, Columbus, OH, USA) with free access to 
standard rat powder food (RM1 811004, Scanbur BK AS, Sweden) and tap water. This system 
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is composed of a four-chamber open circuit indirect calorimeter designed for continuous 
monitoring of individual rats. Eating behavior and metabolic parameters were recorded 
automatically. High-resolution feeding data was generated by monitoring all feeder balances 
every 0.5 s. The end of an eating event (meal) was determined when the balances were stable 
for more than 10 s and a minimum of 0.05 g of food were eaten. An air sample was 
withdrawn every 5 min. Energy expenditure (EE) (kcal/h) was calculated according to the 
equation: (3.815+1.232 RER) × VO2, where RER (respiratory exchange ratio) was the volume 
of CO2 produced per volume of O2 consumed. VO2 was the volume of O2 consumed per h per 
kilogram of mass of the animal. Parameters that were obtained during daytime (7 am–7 pm) 
and nighttime (7 pm–7 am) for each individual rat included number of meals, meal size, meal 
duration, accumulated food intake, intermeal interval, rate of eating, satiety ratio, drinking 
activity, energy expenditure and ambulatory activity. The intermeal interval was defined as 
the interval in minutes between two meals. Rate of eating was calculated by dividing the 
average meal size by the average duration of a meal, and satiety ratio, an index of the non-
eating time produced by each gram of food consumed, was calculated by dividing the average 
intermeal interval by the average meal size. 
In all studies performed food intake was higher and satiety ratio lower during 
nighttime than daytime for all animals at every timepoint. 
 
Gastric acid output measurement 
The rats were fasted for 24h before measurement. Gastric acid output was collected for 
30 min at baseline, 0.5 mA, 1.0 mA, 2.0 mA, 3.5 mA and at the same settings with 
pentagastrin subcutaneous injection (10 µg/kg). Between each collection the stimulation was 
turned off and there was a break of 90 min. The rats received 1 ml physiological saline 
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subcutaneously every second hour. The gastric acid was investigated for pH, H+-secretion and 
amount (ml). 
 
Taqman array 
Hindbrain (medulla and pons) and hypothalamus were dissected at euthanization and 
stored in RNAlater (Qiagen) at -80°C. Brain samples were then homogenized in Qiazol 
(Qiagen, Hilden, Germany) using a TissueLyzer. Total RNA was extracted using RNeasy 
Lipid Tissue Mini Kit (Qiagen), both with additional DNAse treatment (Qiagen). RNA 
quality and quantity were assessed by spectrophotometric measurements (Nanodrop 1000, 
NanoDrop Technologies, USA). For cDNA synthesis, total RNA was reversed transcribed 
using random hexamers (Applied Biosystems, Sundbyberg, Sweden), and Superscript III 
reverse transcriptase (Invitrogen Life Technologies, Paisley, UK), according to the 
manufacturer's description. Recombinant RNaseout® Ribonuclease Inhibitor (Invitrogen) was 
added to prevent RNase-mediated degradation. Samples were run in duplicates. Real-time RT 
PCR was performed using TaqMan®Low Density Array (LDA) custom-made platforms. 
Platfoms were designed with TaqMan probe and primer sets for target genes chosen from an 
on-line catalogue (Applied Biosystems). The sets were factory-loaded into the wells of 
TaqMan® LDAs. Each port on the LDA card was loaded with cDNA corresponding to 100 
ng total RNA, combined with nuclease free water and 50 µl TaqMan® Gene Expression 
Master Mix (Applied Biosystems) to a final volume of 100 µl. The LDA cards were analyzed 
using the 7900HT system with a TaqMan LDA Upgrade (Applied Biosystems). Thermal 
cycling conditions were: 50°C for 2 min, 94.5°C for 10 min, followed by 40 cycles of 97°C 
for 30 s, and 59.7°C for 1 min. Gene expression values were calculated based on the Ct 
method (Livak 2001), where the saline-treated group was designated the calibrator. 
Hydroxymethylbilane synthase (hmbs) was used as reference gene. Target genes as well as 
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the primer sets were Hmbs, Foxa2, Npy, Lepr, Insr, Cckbr, Mc4r, Il1b, Tnf, Tgfb1 (catalogue 
number Rn00565886_m1,  Rn01415600_m1, Rn01410145_m1, Rn01433205_m1, 
Rn00567070_m1, Rn00565867_m1, Rn01491866_s1, Rn00580432_m1, Rn01525859_g1 and 
Rn00572010_m1, respectively). 
 
In situ hybridization 
Brain samples were taken at euthanization and snap-freezed in isopentane on dry ice 
before stored at -80°C wrapped in alufolie. The frozen brains were cut (14 µm) in the region 
spanning the hypothalamus between Bregma –0.10 to –2.54 mm and brainstem (NTS) 
according to the Mouse Brain Atlas of Franklin & Paxinos 1997 and sections were mounted 
onto poly-L-lysine-coated slides.  Briefly, sections were fixed in 4% paraformaldehyde in 0.1 
M phosphate buffer (PB), washed in 0.1 M PB, acetylated in 0.25% acetic anhydrate in 0.1 M 
triethanolamine, and washed again in PB. Sections were dehydrated using graded ethanol. 
DNA templates for the generation of anti-sense riboprobes for AgRP and POMC were 
generated by PCR. Briefly, primers for the amplification of AgRP were based on Genbank 
sequence U89484 to amplify the sequence between bases 113-341 (forward primer 5’-
TGTTCCCAGAGTTCCCAGGTC-3’, reverse primer 5’-
GCATTGAAGAAGCGGCAGTAGCAC-3’). Primers for the amplification of POMC were 
based on Genbank sequence J00162 to amplify the sequence between bases 263-665 (forward 
primer 5’-GGGCAAGCGCTCCTACTCCAT-3’, reverse primer 5’-
GCCCTTCTTGTRSRCGTTCTTGA-3’). The DNA sequence for NPY was a full-length 
cloned rat NPY gene sequence. 35S antisense probes were made using 150ng amplified cloned 
insert bearing transcription factor binding sites using T7 (AgRP), T3 (NPY) or SP6 (POMC) 
RNA polymerase as stated. The radioactive probes were applied to the slides in 70 µl 
hybridization mixture (0.3 M NaCl, 10 mM Tris-HCL (pH 8), 1 mM EDTA, 0.05% transfer 
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RNA, 10 mM dithiothreitol, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% BSA and 10% 
dextran sulphate) and hybridized overnight at 58°C. Post-hybridization, slides were rinsed in 
4x SSC and treated with ribonuclease A (20 µg/µl) at 37°C before being washed in decreasing 
concentrations of SSC and dehydrated using graded ethanol. Slides were dried and exposed to 
Kodak Biomax MR film for various lengths of time. Autoradiographic films were scanned at 
600 dpi on an Epson scanner linked to a computer running Image-Pro PLUS version 
Autoradiographic films were scanned at 600 d.p.i. and analysed using Image Pro Plus v.7.0 
(Media Cybernetics UK, Marlow, Bucks, UK), analysis software (Media Cybernetics UK, 
Wokingham, UK). Integrated optical density was obtained by reference to the 14C microscale. 
NPY, POMC and AgRP mRNA expression was measured in three sections NPYmRNAs were 
quantified from 3 sections containing the NTS. Values were averaged for each animal.  
 
RNA sequencing 
Hippocampus was dissected at euthanization and stored in RNAlater (Qiagen) at -
80°C. Total RNA was isolated using an Ultra-Turrax rotating-knife homogenizer and the 
mirVana™ miRNA Isolation Kit (AM1560, Ambion, USA) according to the manufacturer’s 
instructions. Concentration and purity of total RNA were assessed using a NanoDrop 
(NanoDrop Technologies, Inc., Wilmington, DE, USA) photometer. The A260/280 ratios 
were 2.09 ± 0.02 (mean ± SEM). RNA integrity was assessed using a Bioanalyzer (Agilent 
Technologies, Palo Alto, CA, USA) and found satisfactory with RIN values 9.1±0.3. High-
throughput cDNA sequencing (RNA-seq) was performed at Norwegian Sequencing Centre, 
Dept. of Medical Genetics Ullevål, Oslo University Hospital, using HiSeq2000. Differential 
expression analysis on the data was performed, where reads for all samples were aligned to 
the rat genome and differential expression was calculated using cuffcompare in the Cufflinks 
package. 
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Radioimmunoassay 
Plasma samples were collected at euthanization and kept at -80°C. Radioimmunoassay 
was performed to analyze GLP-1, PYY, gastrin, CCK and glucagon using specific antibodies 
with commercially available kets. Results were expressed  as pmol/l (GLP-1, gastrin, CCK, 
glucagon) and pg/ml (PYY). 
 
In vivo electrophsyiology 
Rats were anaesthetized with 0.1ml/100gr i.m. Hypnorm and 0.05ml/100gr i.p. 
Midazolam. Anesthesia was maintained for the duration of surgery and recordings through 
additional administration of Hypnorm (i.e. 10% every half hour). Eye drops (CAF; ceva Sante 
Animale b.v., Naaldwijk, The Netherlands) were given for the duration of the experiment. 
Body temperature was maintained at 37.5°C by means of a heating pad.  Following placement 
of the VBLOC, as previously described, the animals were mounted in a stereotaxic frame 
(Kopf Instruments) and the cranium was exposed. At this time a local anesthetic was applied 
to the skull (Xylocaine spray; 10%, Astra, Hässle AB, Mölndal, Sweden). A hole was drilled 
over the hippocampal area (coordinates AP -3.2, ML 2.2; Paxinos and Watson, 2005), the 
dura was removed, and a bundle 4 tetrodes (0.005”, Pt/Ir, Fine Wire, California, US) were 
lowered into the brain (DV -3.2) until stable neuronal activity was measured. The drill hole 
was subsequently filled with mineral oil (Sigma-Aldrich Chemie B.V., Zwijndrecht, The 
Netherlands) and a surgical screw was placed into the scull to serve as ground. Following 
measurements animals were sacrificed with an overdose of sodium pentobarbital. During 
VBLOC (at 2.0 mA, 30 Hz, 500 µs, 30 s ON and 5 min OFF) data was recorded at 40Khz 
using a Multineuron Acquisition Processor (MAP) recording system (Plexon, Dallas, USA). 
Signals were passed through a unity-gain amplifier (20×), amplified and filtered with a Plexon 
16-channel preamplifier (PBX3 /16sp-r-G50, 50x amplification, 150-8000 Hz filtered). 
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Subsequently, a 1200µs digitized data sample was stored by the MAP system whenever the 
signal crossed a preset voltage threshold. The data were subsequently analyzed with offline 
cluster cutting procedures based on the average waveforms across the four leads of each 
tetrode (Offline Sorter x64 V3; Plexon).  
 
 
